Dr. Matthias G. Schroff Ph.D. serves as Chief Operating Officer of the Company. He has served as our Chief Operating Officer since April 2018. Dr. Schroff brings more than 15 years of senior leadership experience within global biopharmaceutical companies where he gained deep scientific and clinical experience in immuno-oncology, TLR9 biology and broad clinical program management. Prior to joining us, from September 2016 until December 31 2017, Dr. Schroff served as the chief executive officer for VAXIMM AG, a Swiss/German biotech company. From January 2008 until December 31, 2015, Dr. Schroff was the chief executive officer of Mologen AG, a publicly traded German biopharmaceutical company. Dr. Schroff is the co-inventor on numerous patents in the field of immuno-oncology, RNAi and gene expression, including a TLR9 agonist that is now in late-stage clinical development for various cancer indications. He received his Ph.D. in molecular biology from Freie Universität Berlin and a degree in biochemistry from Leibniz Universität Hannover.
As the Chief Operating Officer of Exicure Inc, the total compensation of Matthias Schroff at Exicure Inc is $476,313. There are 1 executives at Exicure Inc getting paid more, with David Giljohann having the highest compensation of $785,462.
Matthias Schroff is 52, he's been the Chief Operating Officer of Exicure Inc since 2018. There are 6 older and 5 younger executives at Exicure Inc. The oldest executive at Exicure Inc is David Walt, 67, who is the Independent Director.
Matthias's mailing address filed with the SEC is C/O EXICURE, INC., 2430 N. HALSTED ST., CHICAGO, IL, 60614.
Over the last 6 years, insiders at Exicure Inc have traded over $4,850,172 worth of Exicure Inc stock and bought 7,217,940 units worth $10,705,021 . The most active insiders traders include Timothy P Walbert, Co., Ltd. Dgp oraz Usa, Inc. Cbi. On average, Exicure Inc executives and independent directors trade stock every 90 days with the average trade being worth of $928,360. The most recent stock trade was executed by Co., Ltd. Dgp on 29 February 2024, trading 3,400,000 units of XCUR stock currently worth $4,488,000.
exicure, formerly aurasense therapeutics, is developing a new class of immunomodulatory and gene silencing drugs against validated targets. our 3-dimensional, spherical nucleic acid (sna™) architecture unlocks the potential of nucleic acid therapeutics in multiple organs. our lead programs address diseases from inflammatory disorders to oncology. sna constructs overcome one of the most difficult obstacles to nucleic acid therapeutics: safe and effective delivery into cells and tissues. sna constructs exhibit unparalleled transfection efficiency into numerous cell and tissue types including the skin without carriers or transfection agents. moreover, snas can be used as potent immunotherapeutic agents for the treatment of cancer or infectious disease.
Exicure Inc executives and other stock owners filed with the SEC include: